BioAtla raises $189m for IPO
BioAtla Inc, a developer of therapeutics for treating solid tumor cancer, has raised $189 million for its IPO after pricing its 10.5 million shares at $18 per share.
16 December 2020•2 mins read
BioAtla Inc, a developer of therapeutics for treating solid tumor cancer, has raised $189 million for its IPO after pricing its 10.5 million shares at $18 per share.
Walter Capital Partners takes significant stake in Quebec educational games maker Passe-Temps
6 November 2026 · 1 min read
Truelink Capital’s GES buys CSG Creative from National Trade Productions
6 November 2026 · 2 mins read
MPE Partners’ Intermatic adds outdoor lighting-control products maker Sun-Tech
6 November 2026 · 2 mins read
Velocity Capital Management backs founder Griffin Haddrill with stake in LV8, Mirage
6 November 2026 · 1 min read
Aterian’s Outlook Group completes acquisition of Graham-backed ABX’s Pewaukee packaging facility
6 November 2026 · 1 min read
FPE Capital’s NoBlue2 adds PeopleWalking’s Spanish NetSuite business in Europe push
6 November 2026 · 1 min read
PE targets identity security as AI transforms threats: 6 deals
6 November 2026 · 3 mins read
